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Since the initial report of an enrichment of the APOE 4 allele of the Apolipoprotein E ( 
APOE) gene among Alzheimer disease (AD) patients (Saunders et al. 1993), the strength of 
the association between different APOE genotypes and the disease is reported as odds ratios 
(ORs). Taking as a basis the most frequent genotype (APOE 33), the odds ratios are estimated 
to be 3.2 for APOE 34 and 14.9 for APOE 44 whereas, the APOE 2 allele has a protective 
effect in Caucasian subjects (Farrer et al. , 1997). However, ORs, that are basically 
epidemiological measures, are of limited interest in medical practise. What the physician (and 
the carrier of an “ at risk “ genotype) want to know is not the magnitude of the increased risk 
conferred by this particular genotype with respect to the most frequent genotype in the 
population but the actual probability to develop the disease according to age and sex. To 
address this issue, we (Bickeboller et al. 1997) and others ( Myers et al. 1996 , Seshadri et al. 
1995) previously attempted to calculate genotype-dependent AD lifetime risks (LTRs); i.e. 
the risk to develop the disease between birth and some particular age t (Thompson and 
Weissman, 1981). The LTR of a given APOE genotype could also be seen as the penetrance 
at age t of AD among carriers of this APOE genotype or the probability that a randomly 
selected individual with this APOE genotype will develop AD by that age assuming that he 
does not die of another cause before that age (Satagopan et al. 2001).  
However, due to the limited sample sizes available at that time, 95% confidence intervals 
(95% CI) were huge and precluded any reasonable estimate of LTRs especially in APOE 4 
homozygotes. Taking advantage of the large case/control sample used in a recent European 
AD Genome wide association study (GWAS) (Lambert et al. 2009) and adding two novel 
case/control cohorts, we undertook a novel attempt to estimate these values. 
All subjects included in the GWAS as well as 2,971 new Caucasian subjects (1398 controls 
and 1573 AD patients) originating from the west of France and the USA and ascertained 
according to the same criteria than the GWAS subjects were included in this study. Therefore, 
 3 
a total of 7,531 cases and 10,132 controls from seven different sub-studies were available. 
Demographic characteristics of the samples are summarized in Table 1. 
Individuals were stratified into 4 age categories (less than 60, between 60 and 69, between 70 
and 79 and more than 80 years old) depending on either the age of onset of the disease for 
patients or the current age for controls. APOE genotype frequency estimates and their 95% CI 
are shown in Figure S1 for cases and controls in the different samples stratified by age (males 
and females were considered together as no frequency difference was found between gender). 
After stratification on age, only limited heterogeneity could be seen between samples and we 
thus decided to pool them all. Table 2 gives the ORs (taking APOE 33 as reference) obtained 
for the different APOE genotypes on the pooled data in the different age categories and over 
all age categories. The OR of APOE 44 in the whole sample (OR=14.49; 95%CI = [11.91; 
17.64]) is consistent with previous estimates (Farrer et al. 1997) but varies significantly with 
age, ranging from 5.6 (95%CI = [3.17; 9.89]) when the onset is before the age of 60 years old 
to 35.07 (95%CI = [23.8; 51.68]) when the onset is between 60 and 69. The same if true for 
APOE 34 with ORs in the range between 2.09 (95%CI= [1.61; 2.71]) for patients with an 
onset before 60 years and 4.18 (95%CI=[3.59; 4.88]) for the patients with an onset between 
70 and 79 years. For the other APOE genotypes, ORs are more homogeneous across age-
groups and are estimated to be 2.64 [2.13; 3.27] for APOE 24 and 0.56 [0.49; 0.64] for APOE 
22 and 23 considered together.  
Age dependant penetrances of the different APOE genotypes were computed using a method 
similar to those described in Bickeboller et al. (1997) and Satagopan et al. (2001). The only 
difference is that in our computation we account for mortality rates over the different age and 
genotype categories (see Supplementary Data for a description of the method used).  
 
The AD LTR estimates according to age, sex and APOE genotype are presented in Table 3.  
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At age 85, they reach 51 % (95%CI=[41;69]) and 56% (95%CI=[45;75]) for APOE 44 male 
and female carriers and 23% (95%CI=[22;25]) and 26% (95%CI=[24;28]) for APOE 34 male 
and female carriers, consistent with semi dominant inheritance of a moderately penetrant 
gene. Clearly these values indicate that the effect of APOE on Alzheimer disease is more 
similar to the one of major genes in mendelian diseases such as BRCA1 in breast cancer than 
the one of low-risk common alleles identified by recent GWASs in complex diseases. For a 
comparison, the lifetime risk of breast cancer in BRCA1 mutation carriers by age 70 is 
estimated to be around 57% (95% CI, 47% to 66%), so very similar to our estimated APOE 
44 penetrances by age 85 (Chen and Parmigiani ; 2007). 
The allelic frequency of the APOE 4 allele in human populations ranges from 0.09 to 0.19 
(Farrer et al. 1997). These values are well above those found for other deleterious alleles 
responsible for mendelian diseases, even those involved in recessive disorders. This apparent 
paradox might be explained by the fact that the APOE 4 allele, that is probably the ancestral 
APOE allele in humans (Fullerton et al., 2000), exerts its deleterious effect mainly in elderly 
individuals. Its impact on the reproductive fitness of the carriers is probably very limited. 
However, its reduced frequency compared to the one of the APOE 3 allele, if not due to 
genetic drift, suggests that it might slightly reduce the fitness.  
As discussed by Yang et al. (Yang et al. 2009), lifetime risk estimates suffer from 
uncertainties in the population incidence rates, genotype frequencies and effect sizes. By 
using a bootstrap method, we were able to account for these two latter uncertainties but since 
we had to rely on published records of incidence rates, we were not able to model 
uncertainties in incidence rates. We also had to account for the fact that mortality rates vary 
depending on APOE genotypes. In particular, the APOE 4 allele has been shown to increase 
cardiovascular mortality (Schachter et al. 1994) and a recent GWAS confirmed that the APOE 
locus plays a role in longevity as this locus stands up among the ones with the most extreme 
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allele frequencies differences in centenarians compared to younger controls (Sebastiani, et al. 
2010). To account for mortality differences depending on APOE genotypes in LTRs 
computations, we built a new model that assumes that for a given APOE genotype, survival 
probabilities are proportional to the genotype frequency differences observed over the 
different age categories in the sample (see supplementary data).  
In conclusion, we think that our results urge for a shift of category of the APOE gene from 
“risk factor” to “major gene”. This shift is not a pure semantic exercise. It has profound 
implications for patients. In Caucasian populations roughly 2% of the population bears an 
APOE 44 genotype. Considering the major risk conferred by this genotype, it becomes 
necessary to target at a presymptomatic state these individuals , as well as PSENs or APP 
mutation carriers, in clinical trials aimed at developing novel preventive therapeutics. 
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SPAIN 755 75.31 
(9.33) 
0.54 849 76.05 
(12.37) 
0.53 
FINLAND 586 71.38 
(7.50) 
0.47 663 69.14 
(6.09) 
0.67 
FRANCE 1 2 025 73.66 
(8.91) 
0.53 5 328 73.83 
(5.42) 
0.63 
ITALY 1 513 76.62 
(8.72) 
0.48 1 338 70.76 
(11.83) 
0.80 
USA 934 72.86 
(6.26) 
0.48 866 73.85 
(6.36) 
0.68 
FRANCE 2 639 63.99 
(9.88) 
0.60 532 66.13 
(12.01) 
0.89 
BELGIUM 1 079 78.56 
(8.10) 
0.51 556 64.20 
(15.29) 
0.75 
TOTAL 7 531 74.03 
(9.27) 
0.51 10 132 72.37 
(9.06) 
0.67 






Age-group Sample Size (Cases/Controls) APOE 44 APOE 34 APOE 24 APOE 22+23 
Less than 60 593 / 610 5.60 [3.17;9.89] 2.09 [1.61;2.71] 1.29 [0.61;2.71] 0.43 [0.24;0.77] 
60 to 70 1511 / 2614 35.07 [23.8;51.68] 4.18 [3.59;4.88] 2.2 [1.32;3.68] 0.59 [0.43;0.82] 
70 to 80 3244 / 5175 15.75 [11.93;20.8] 4.54 [4.09;5.05] 2.79 [2.05;3.8] 0.51 [0.41;0.63] 
More than 80 2183 / 1733 7.87 [4.28;14.46] 3.16 [2.68;3.72] 3.77 [2.28;6.23] 0.59 [0.47;0.74] 
All 7531/10132 14.49 [11.91; 17.64] 3.63 [3.37; 3.90] 2.64 [2.13; 3.27] 0.56 [0.49; 0.64] 
p-valuea  1.05×10-7 3.40×10-8 0.11  0.64 
 








Age Gender APOE 44 APOE 34 APOE 24 APOE 33 APOE 22+23 
65 Male 4.14 [1.48;10.19] 1.02 [0.83;1.27] 0.28 [0.09;0.81] 0.28 [0.25;0.32] 0.21 [0.13;0.34] 
 Female 4.25 [1.52;10.46] 1.06 [0.85;1.31] 0.29 [0.09;0.84] 0.29 [0.26;0.32] 0.22 [0.13;0.34] 
75 Male 28.35 [21.21;43.63] 6.96 [6.35;7.62] 4.39 [3.14;6.80] 1.77 [1.69;1.86] 1.12 [0.92;1.38] 
 Female 29.89 [22.39;45.96] 7.36 [6.72;8.06] 4.65 [3.32;7.19] 1.88 [1.79;1.97] 1.18 [0.97;1.47] 
85 Male 50.92 [41.08;68.65] 23.22 [21.64;25.05] 19.99 [14.10;29.51] 7.76 [7.46;8.05] 4.87 [4.20;5.67] 
 Female 56.03 [45.43;75.40] 26.09 [24.33;28.14] 22.55 [15.92;33.30] 8.76 [8.43;9.09] 5.51 [4.75;6.41] 
 
Table 3  Penetrance estimates [95% Confidence Interval] (%) of the different APOE genotypes by different ages in males and females after 
accounting for APOE genotype differential effect on mortality using the model described in Supplementary Data.  
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